Recce Pharmaceuticals Ltd, a biotechnology company, discovers, develops, and commercializes synthetic anti"infectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use. In addition, the company engages in R327 Intravenous that has completed Phase I clinical trial for the treatment of urinary tract infections/urosepsis; UTI/urosepsis rapid infusions sepsis that has completed Phase II trial; and R327 Topical Gel for the treatment of acute bacterial skin and skin structure infections, as well as post operative infaction, wound infections and diabetic foot infections that in Phase 2 trails. Further, the company operates various pre-clinical programs, such as Neisseria gonorrhoeae; Mycobacterium abscessus; and Escherichia coli (E. coli) in urinary tract infection. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia. Address: Salesforce Tower, Sydney, NSW, Australia, 2000